| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiac Surgical Procedures | 68 | 2022 | 173 | 9.470 |
Why?
|
| Heart Defects, Congenital | 41 | 2022 | 94 | 9.410 |
Why?
|
| Heart Valve Prosthesis Implantation | 32 | 2022 | 64 | 5.150 |
Why?
|
| Hypoplastic Left Heart Syndrome | 16 | 2025 | 27 | 4.750 |
Why?
|
| Heart Valve Prosthesis | 22 | 2020 | 62 | 4.310 |
Why?
|
| Fontan Procedure | 12 | 2020 | 24 | 3.470 |
Why?
|
| Aortic Coarctation | 11 | 2022 | 21 | 3.350 |
Why?
|
| Pulmonary Valve | 10 | 2022 | 14 | 3.190 |
Why?
|
| Mitral Valve | 23 | 2023 | 63 | 2.930 |
Why?
|
| Aorta, Thoracic | 13 | 2022 | 55 | 2.860 |
Why?
|
| Tetralogy of Fallot | 12 | 2022 | 23 | 2.660 |
Why?
|
| Humans | 215 | 2025 | 28581 | 2.570 |
Why?
|
| Aortic Valve | 22 | 2021 | 92 | 2.570 |
Why?
|
| Extracorporeal Membrane Oxygenation | 7 | 2019 | 30 | 2.400 |
Why?
|
| Heart Ventricles | 16 | 2022 | 139 | 2.320 |
Why?
|
| Heart Septal Defects | 8 | 2021 | 10 | 2.280 |
Why?
|
| Norwood Procedures | 5 | 2022 | 13 | 2.220 |
Why?
|
| Heart Septal Defects, Ventricular | 10 | 2022 | 19 | 2.180 |
Why?
|
| Mitral Valve Insufficiency | 19 | 2018 | 43 | 2.150 |
Why?
|
| Infant | 49 | 2025 | 1019 | 2.110 |
Why?
|
| Treatment Outcome | 88 | 2025 | 2402 | 2.110 |
Why?
|
| Robotics | 13 | 2015 | 43 | 2.060 |
Why?
|
| Blood Vessel Prosthesis Implantation | 8 | 2018 | 36 | 1.960 |
Why?
|
| Bioprosthesis | 11 | 2020 | 21 | 1.940 |
Why?
|
| Pulmonary Atresia | 7 | 2022 | 8 | 1.910 |
Why?
|
| Heart Valve Diseases | 10 | 2023 | 26 | 1.910 |
Why?
|
| Vascular Surgical Procedures | 10 | 2020 | 54 | 1.880 |
Why?
|
| Pulmonary Artery | 13 | 2022 | 69 | 1.870 |
Why?
|
| Aortic Valve Insufficiency | 7 | 2020 | 21 | 1.810 |
Why?
|
| Cardiopulmonary Bypass | 16 | 2021 | 41 | 1.790 |
Why?
|
| Aortic Valve Stenosis | 9 | 2020 | 85 | 1.770 |
Why?
|
| Male | 134 | 2025 | 13771 | 1.680 |
Why?
|
| Mitral Valve Prolapse | 14 | 2023 | 21 | 1.670 |
Why?
|
| Female | 137 | 2025 | 15471 | 1.630 |
Why?
|
| Reoperation | 35 | 2015 | 153 | 1.560 |
Why?
|
| Retrospective Studies | 71 | 2022 | 2612 | 1.550 |
Why?
|
| Pulmonary Valve Insufficiency | 5 | 2022 | 6 | 1.510 |
Why?
|
| Postoperative Complications | 29 | 2019 | 631 | 1.500 |
Why?
|
| Palliative Care | 9 | 2022 | 84 | 1.450 |
Why?
|
| Tricuspid Valve | 13 | 2022 | 31 | 1.390 |
Why?
|
| Cord Blood Stem Cell Transplantation | 3 | 2025 | 7 | 1.300 |
Why?
|
| Cardiovascular Abnormalities | 3 | 2020 | 7 | 1.270 |
Why?
|
| Time Factors | 47 | 2019 | 1600 | 1.210 |
Why?
|
| Aorta | 12 | 2022 | 124 | 1.200 |
Why?
|
| Follow-Up Studies | 43 | 2018 | 1026 | 1.200 |
Why?
|
| Subclavian Artery | 4 | 2016 | 14 | 1.190 |
Why?
|
| Ventricular Septum | 2 | 2019 | 3 | 1.180 |
Why?
|
| Coronary Vessel Anomalies | 12 | 2017 | 26 | 1.120 |
Why?
|
| Middle Aged | 86 | 2020 | 7310 | 1.120 |
Why?
|
| Vena Cava, Superior | 5 | 2019 | 27 | 1.110 |
Why?
|
| Computer Simulation | 7 | 2022 | 231 | 1.110 |
Why?
|
| Child, Preschool | 42 | 2025 | 1167 | 1.110 |
Why?
|
| Adult | 80 | 2020 | 7922 | 1.080 |
Why?
|
| Thoracic Surgery | 5 | 2016 | 14 | 1.040 |
Why?
|
| Aortic Aneurysm | 4 | 2017 | 15 | 1.040 |
Why?
|
| Coronary Artery Bypass | 12 | 2020 | 68 | 1.010 |
Why?
|
| Tricuspid Valve Insufficiency | 11 | 2020 | 16 | 1.000 |
Why?
|
| Child | 42 | 2025 | 2271 | 0.900 |
Why?
|
| Pulmonary Circulation | 3 | 2014 | 15 | 0.900 |
Why?
|
| Surgery, Computer-Assisted | 5 | 2012 | 33 | 0.890 |
Why?
|
| Pulmonary Veno-Occlusive Disease | 2 | 2020 | 4 | 0.880 |
Why?
|
| Survival Rate | 27 | 2019 | 431 | 0.880 |
Why?
|
| Pulmonary Veins | 4 | 2020 | 108 | 0.870 |
Why?
|
| Regeneration | 4 | 2020 | 77 | 0.850 |
Why?
|
| Forecasting | 3 | 2014 | 76 | 0.840 |
Why?
|
| Echocardiography | 17 | 2014 | 108 | 0.830 |
Why?
|
| Truncus Arteriosus, Persistent | 2 | 2022 | 4 | 0.820 |
Why?
|
| Adolescent | 52 | 2016 | 3165 | 0.820 |
Why?
|
| Aged | 61 | 2020 | 5525 | 0.820 |
Why?
|
| Heart | 3 | 2020 | 224 | 0.800 |
Why?
|
| Ventricular Function, Right | 4 | 2020 | 13 | 0.800 |
Why?
|
| Infant, Newborn | 23 | 2022 | 899 | 0.800 |
Why?
|
| Chordae Tendineae | 4 | 2020 | 11 | 0.790 |
Why?
|
| Stem Cell Transplantation | 2 | 2020 | 18 | 0.780 |
Why?
|
| Internship and Residency | 4 | 2016 | 250 | 0.760 |
Why?
|
| Printing, Three-Dimensional | 2 | 2020 | 31 | 0.750 |
Why?
|
| Reconstructive Surgical Procedures | 4 | 2016 | 72 | 0.710 |
Why?
|
| Spherocytosis, Hereditary | 1 | 2021 | 4 | 0.710 |
Why?
|
| Computer-Assisted Instruction | 2 | 2013 | 30 | 0.700 |
Why?
|
| Vocal Cord Paralysis | 2 | 2019 | 5 | 0.690 |
Why?
|
| Heart Atria | 5 | 2013 | 176 | 0.680 |
Why?
|
| Stenosis, Pulmonary Vein | 1 | 2020 | 1 | 0.670 |
Why?
|
| Tomography, X-Ray Computed | 15 | 2016 | 478 | 0.660 |
Why?
|
| Angioplasty, Balloon | 2 | 2018 | 21 | 0.650 |
Why?
|
| Fistula | 1 | 2020 | 17 | 0.650 |
Why?
|
| Minnesota | 26 | 2015 | 42 | 0.650 |
Why?
|
| Physician-Patient Relations | 1 | 2021 | 116 | 0.640 |
Why?
|
| Heart Diseases | 4 | 2016 | 71 | 0.630 |
Why?
|
| Thrombosis | 4 | 2022 | 150 | 0.630 |
Why?
|
| Arterial Occlusive Diseases | 3 | 2018 | 44 | 0.630 |
Why?
|
| Young Adult | 44 | 2018 | 2804 | 0.620 |
Why?
|
| Device Removal | 2 | 2019 | 30 | 0.620 |
Why?
|
| Mitral Valve Annuloplasty | 4 | 2014 | 5 | 0.620 |
Why?
|
| Postoperative Care | 7 | 2015 | 68 | 0.610 |
Why?
|
| Aneurysm | 2 | 2016 | 25 | 0.610 |
Why?
|
| Deglutition Disorders | 2 | 2016 | 24 | 0.610 |
Why?
|
| Scimitar Syndrome | 1 | 2019 | 6 | 0.600 |
Why?
|
| Catheters | 1 | 2019 | 24 | 0.590 |
Why?
|
| Aortic Diseases | 1 | 2018 | 17 | 0.590 |
Why?
|
| Hospitals, Pediatric | 1 | 2019 | 31 | 0.590 |
Why?
|
| Hemodynamics | 11 | 2018 | 221 | 0.580 |
Why?
|
| Pericardium | 6 | 2016 | 47 | 0.580 |
Why?
|
| Diaphragm | 1 | 2018 | 16 | 0.580 |
Why?
|
| Phrenic Nerve | 1 | 2018 | 23 | 0.570 |
Why?
|
| Ventricular Outflow Obstruction | 5 | 2013 | 11 | 0.570 |
Why?
|
| Vascular Stiffness | 1 | 2018 | 41 | 0.570 |
Why?
|
| Heart Septal Defects, Atrial | 8 | 2014 | 16 | 0.570 |
Why?
|
| Heart Aneurysm | 3 | 2011 | 10 | 0.560 |
Why?
|
| Foreign-Body Migration | 2 | 2013 | 8 | 0.540 |
Why?
|
| Risk Factors | 25 | 2019 | 2111 | 0.540 |
Why?
|
| Double Outlet Right Ventricle | 4 | 2013 | 4 | 0.530 |
Why?
|
| Fetal Blood | 3 | 2025 | 40 | 0.520 |
Why?
|
| Strongyloidiasis | 2 | 2013 | 3 | 0.520 |
Why?
|
| Cardiovascular Surgical Procedures | 4 | 2010 | 8 | 0.520 |
Why?
|
| Regional Blood Flow | 4 | 2014 | 164 | 0.510 |
Why?
|
| Ebstein Anomaly | 5 | 2014 | 10 | 0.510 |
Why?
|
| Esophageal Stenosis | 1 | 2016 | 3 | 0.510 |
Why?
|
| Aneurysm, False | 2 | 2015 | 19 | 0.510 |
Why?
|
| Vena Cava Filters | 2 | 2013 | 11 | 0.510 |
Why?
|
| Transposition of Great Vessels | 4 | 2013 | 9 | 0.490 |
Why?
|
| Coronary Angiography | 8 | 2014 | 150 | 0.470 |
Why?
|
| Recovery of Function | 6 | 2019 | 122 | 0.460 |
Why?
|
| Cardiac Catheterization | 7 | 2014 | 114 | 0.460 |
Why?
|
| Aged, 80 and over | 24 | 2018 | 2045 | 0.440 |
Why?
|
| Minimally Invasive Surgical Procedures | 4 | 2016 | 77 | 0.420 |
Why?
|
| Swine | 11 | 2022 | 238 | 0.420 |
Why?
|
| Dexamethasone | 1 | 2013 | 63 | 0.410 |
Why?
|
| Hydrocortisone | 1 | 2013 | 89 | 0.400 |
Why?
|
| Risk Assessment | 20 | 2014 | 622 | 0.400 |
Why?
|
| Glucocorticoids | 1 | 2013 | 115 | 0.400 |
Why?
|
| Tricuspid Valve Prolapse | 1 | 2012 | 1 | 0.390 |
Why?
|
| Hemoglobins | 2 | 2013 | 118 | 0.390 |
Why?
|
| Heart Failure | 5 | 2016 | 250 | 0.390 |
Why?
|
| Kaplan-Meier Estimate | 16 | 2015 | 194 | 0.380 |
Why?
|
| Sternotomy | 5 | 2014 | 7 | 0.380 |
Why?
|
| Decision Making | 1 | 2014 | 177 | 0.370 |
Why?
|
| Patient Selection | 13 | 2016 | 149 | 0.370 |
Why?
|
| Transplantation, Homologous | 2 | 2010 | 48 | 0.370 |
Why?
|
| Severity of Illness Index | 14 | 2018 | 461 | 0.360 |
Why?
|
| Tricuspid Atresia | 2 | 2009 | 2 | 0.360 |
Why?
|
| Transplantation, Autologous | 4 | 2025 | 42 | 0.350 |
Why?
|
| Arteriovenous Shunt, Surgical | 3 | 2010 | 25 | 0.350 |
Why?
|
| Prospective Studies | 9 | 2019 | 1272 | 0.340 |
Why?
|
| Heart Transplantation | 3 | 2016 | 43 | 0.340 |
Why?
|
| Transplantation, Heterologous | 1 | 2010 | 60 | 0.340 |
Why?
|
| Collateral Circulation | 5 | 2022 | 12 | 0.340 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2025 | 82 | 0.340 |
Why?
|
| Heart Septum | 3 | 2013 | 16 | 0.330 |
Why?
|
| Cohort Studies | 14 | 2016 | 893 | 0.330 |
Why?
|
| Myocardial Infarction | 6 | 2013 | 351 | 0.330 |
Why?
|
| Coronary Vessels | 5 | 2017 | 153 | 0.330 |
Why?
|
| Cardiomyopathy, Hypertrophic | 3 | 2015 | 12 | 0.320 |
Why?
|
| Echocardiography, Transesophageal | 4 | 2018 | 43 | 0.310 |
Why?
|
| Hospital Mortality | 11 | 2015 | 157 | 0.310 |
Why?
|
| Abnormalities, Multiple | 4 | 2014 | 35 | 0.310 |
Why?
|
| Pleural Effusion | 1 | 2009 | 14 | 0.300 |
Why?
|
| Prosthesis Design | 9 | 2014 | 88 | 0.300 |
Why?
|
| Coronary Artery Disease | 3 | 2020 | 218 | 0.300 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2017 | 163 | 0.290 |
Why?
|
| Coronary Aneurysm | 1 | 2008 | 2 | 0.280 |
Why?
|
| Angioplasty | 1 | 2008 | 12 | 0.280 |
Why?
|
| Elastin | 2 | 2021 | 22 | 0.280 |
Why?
|
| Plasticizers | 1 | 2007 | 4 | 0.270 |
Why?
|
| Diethylhexyl Phthalate | 1 | 2007 | 6 | 0.270 |
Why?
|
| Echocardiography, Three-Dimensional | 2 | 2018 | 3 | 0.270 |
Why?
|
| Heart Valves | 2 | 2020 | 10 | 0.270 |
Why?
|
| Imaging, Three-Dimensional | 4 | 2013 | 130 | 0.270 |
Why?
|
| Adenocarcinoma | 2 | 2017 | 300 | 0.260 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2007 | 24 | 0.260 |
Why?
|
| Incidence | 7 | 2019 | 568 | 0.260 |
Why?
|
| Materials Testing | 1 | 2007 | 89 | 0.260 |
Why?
|
| Case-Control Studies | 5 | 2020 | 732 | 0.250 |
Why?
|
| Survival Analysis | 7 | 2014 | 288 | 0.250 |
Why?
|
| Stress, Mechanical | 5 | 2021 | 115 | 0.250 |
Why?
|
| Hospital Costs | 2 | 2018 | 30 | 0.250 |
Why?
|
| Multivariate Analysis | 10 | 2014 | 302 | 0.240 |
Why?
|
| Lung Neoplasms | 2 | 2017 | 357 | 0.240 |
Why?
|
| Education, Medical, Graduate | 2 | 2016 | 117 | 0.240 |
Why?
|
| Biomechanical Phenomena | 6 | 2021 | 182 | 0.240 |
Why?
|
| Animals | 19 | 2023 | 10580 | 0.230 |
Why?
|
| Echocardiography, Doppler | 7 | 2014 | 21 | 0.230 |
Why?
|
| Cause of Death | 4 | 2014 | 73 | 0.230 |
Why?
|
| Diagnosis, Differential | 6 | 2017 | 378 | 0.230 |
Why?
|
| Coronary Stenosis | 3 | 2013 | 20 | 0.230 |
Why?
|
| Clinical Competence | 3 | 2016 | 234 | 0.230 |
Why?
|
| Stents | 2 | 2018 | 121 | 0.220 |
Why?
|
| Prosthesis Failure | 6 | 2016 | 22 | 0.220 |
Why?
|
| Vascular Patency | 6 | 2011 | 44 | 0.220 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2022 | 14 | 0.220 |
Why?
|
| Recurrence | 5 | 2015 | 325 | 0.210 |
Why?
|
| Predictive Value of Tests | 8 | 2017 | 480 | 0.210 |
Why?
|
| Sternoclavicular Joint | 1 | 2003 | 1 | 0.200 |
Why?
|
| Ventricular Function, Left | 5 | 2014 | 112 | 0.200 |
Why?
|
| Aortic Stenosis, Supravalvular | 2 | 2013 | 3 | 0.200 |
Why?
|
| Arterio-Arterial Fistula | 2 | 2012 | 5 | 0.200 |
Why?
|
| Hemophilia A | 2 | 2014 | 15 | 0.190 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 2002 | 1 | 0.190 |
Why?
|
| Pulmonary Surgical Procedures | 1 | 2002 | 1 | 0.190 |
Why?
|
| Carcinoma, Large Cell | 1 | 2002 | 6 | 0.190 |
Why?
|
| Mechanical Phenomena | 1 | 2022 | 21 | 0.190 |
Why?
|
| Age Factors | 9 | 2016 | 734 | 0.190 |
Why?
|
| Collagen | 2 | 2021 | 156 | 0.190 |
Why?
|
| Thorax | 1 | 2002 | 29 | 0.190 |
Why?
|
| Prognosis | 8 | 2015 | 807 | 0.180 |
Why?
|
| Papillary Muscles | 2 | 2020 | 15 | 0.180 |
Why?
|
| Bronchi | 1 | 2022 | 38 | 0.180 |
Why?
|
| Ultrasonography | 8 | 2015 | 241 | 0.180 |
Why?
|
| Exchange Transfusion, Whole Blood | 1 | 2021 | 1 | 0.180 |
Why?
|
| Myocardial Ischemia | 1 | 2022 | 73 | 0.180 |
Why?
|
| Infant, Premature, Diseases | 2 | 2013 | 37 | 0.180 |
Why?
|
| Anticoagulants | 4 | 2013 | 295 | 0.180 |
Why?
|
| Proportional Hazards Models | 7 | 2015 | 226 | 0.170 |
Why?
|
| Sinus of Valsalva | 2 | 2012 | 13 | 0.170 |
Why?
|
| Defibrillators, Implantable | 3 | 2016 | 46 | 0.170 |
Why?
|
| Catheter Ablation | 2 | 2014 | 223 | 0.170 |
Why?
|
| Cardiac Valve Annuloplasty | 3 | 2015 | 4 | 0.170 |
Why?
|
| Constriction, Pathologic | 2 | 2018 | 36 | 0.170 |
Why?
|
| Accidents, Traffic | 1 | 2001 | 28 | 0.170 |
Why?
|
| Blood Vessel Prosthesis | 2 | 2018 | 28 | 0.170 |
Why?
|
| Allografts | 2 | 2017 | 11 | 0.170 |
Why?
|
| Fibrillar Collagens | 1 | 2020 | 7 | 0.170 |
Why?
|
| Atrial Fibrillation | 3 | 2014 | 402 | 0.170 |
Why?
|
| Feasibility Studies | 2 | 2019 | 209 | 0.170 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2020 | 115 | 0.170 |
Why?
|
| Ventricular Remodeling | 2 | 2018 | 32 | 0.170 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2001 | 52 | 0.160 |
Why?
|
| Stroke Volume | 7 | 2014 | 124 | 0.160 |
Why?
|
| Chi-Square Distribution | 7 | 2014 | 145 | 0.160 |
Why?
|
| Diabetic Angiopathies | 1 | 2020 | 48 | 0.160 |
Why?
|
| Cryopreservation | 2 | 2012 | 13 | 0.160 |
Why?
|
| Hematoma | 1 | 2019 | 26 | 0.160 |
Why?
|
| Tendons | 1 | 2019 | 28 | 0.160 |
Why?
|
| Hypertension | 5 | 2013 | 309 | 0.150 |
Why?
|
| Myocytes, Cardiac | 2 | 2022 | 63 | 0.150 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2020 | 27 | 0.150 |
Why?
|
| Longevity | 1 | 2020 | 134 | 0.150 |
Why?
|
| Vocal Cords | 1 | 2019 | 4 | 0.150 |
Why?
|
| Models, Cardiovascular | 1 | 2019 | 47 | 0.150 |
Why?
|
| Perioperative Care | 3 | 2014 | 35 | 0.150 |
Why?
|
| Arrhythmias, Cardiac | 3 | 2016 | 163 | 0.150 |
Why?
|
| Glycosaminoglycans | 1 | 2019 | 55 | 0.150 |
Why?
|
| United States | 4 | 2019 | 2201 | 0.150 |
Why?
|
| Ventricular Function | 1 | 2018 | 25 | 0.150 |
Why?
|
| Syndrome | 1 | 2018 | 79 | 0.150 |
Why?
|
| Biomarkers | 4 | 2020 | 770 | 0.150 |
Why?
|
| Myocardium | 2 | 2017 | 194 | 0.140 |
Why?
|
| Odds Ratio | 6 | 2014 | 236 | 0.140 |
Why?
|
| Wounds, Gunshot | 1 | 1998 | 18 | 0.140 |
Why?
|
| Venous Insufficiency | 1 | 1997 | 2 | 0.140 |
Why?
|
| Parents | 1 | 2019 | 131 | 0.140 |
Why?
|
| Veins | 1 | 1997 | 19 | 0.140 |
Why?
|
| Death, Sudden, Cardiac | 3 | 2016 | 28 | 0.140 |
Why?
|
| Aneurysm, Dissecting | 2 | 2010 | 12 | 0.130 |
Why?
|
| Logistic Models | 6 | 2014 | 409 | 0.130 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2014 | 64 | 0.130 |
Why?
|
| Renal Dialysis | 1 | 1997 | 53 | 0.130 |
Why?
|
| Databases, Factual | 4 | 2014 | 265 | 0.130 |
Why?
|
| Truncus Arteriosus | 1 | 2017 | 2 | 0.130 |
Why?
|
| Hypertrophy, Left Ventricular | 3 | 2013 | 37 | 0.130 |
Why?
|
| Sex Factors | 5 | 2016 | 467 | 0.130 |
Why?
|
| Kidney Failure, Chronic | 1 | 1997 | 70 | 0.130 |
Why?
|
| Anisotropy | 3 | 2022 | 28 | 0.130 |
Why?
|
| Aneurysm, Infected | 2 | 2015 | 3 | 0.130 |
Why?
|
| Femoral Artery | 2 | 2012 | 58 | 0.130 |
Why?
|
| Tissue and Organ Procurement | 1 | 2016 | 10 | 0.130 |
Why?
|
| Pacemaker, Artificial | 3 | 2012 | 56 | 0.130 |
Why?
|
| Intraoperative Complications | 2 | 2014 | 47 | 0.130 |
Why?
|
| Coronary Disease | 2 | 2014 | 120 | 0.130 |
Why?
|
| Angiography | 1 | 2016 | 35 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2020 | 340 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 3 | 2013 | 244 | 0.130 |
Why?
|
| Vena Cava, Inferior | 2 | 2013 | 16 | 0.130 |
Why?
|
| Calcinosis | 2 | 2010 | 25 | 0.130 |
Why?
|
| Anastomosis, Surgical | 3 | 2011 | 38 | 0.130 |
Why?
|
| Thoracotomy | 1 | 2016 | 17 | 0.130 |
Why?
|
| Prosthesis Implantation | 1 | 2016 | 26 | 0.130 |
Why?
|
| Anesthesia | 2 | 2013 | 26 | 0.120 |
Why?
|
| Faculty | 1 | 2016 | 62 | 0.120 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 105 | 0.120 |
Why?
|
| Intensive Care Units, Pediatric | 2 | 2013 | 22 | 0.120 |
Why?
|
| Cardiotonic Agents | 2 | 2014 | 28 | 0.120 |
Why?
|
| Exercise Test | 2 | 2014 | 249 | 0.120 |
Why?
|
| Proteomics | 1 | 2017 | 192 | 0.120 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2015 | 14 | 0.120 |
Why?
|
| Endocarditis, Bacterial | 1 | 2015 | 15 | 0.120 |
Why?
|
| Electrocardiography | 4 | 2011 | 394 | 0.120 |
Why?
|
| Robotic Surgical Procedures | 1 | 2016 | 51 | 0.120 |
Why?
|
| Warfarin | 2 | 2013 | 94 | 0.120 |
Why?
|
| Adaptation, Physiological | 3 | 2022 | 172 | 0.120 |
Why?
|
| Oklahoma | 1 | 2019 | 1038 | 0.120 |
Why?
|
| 22q11 Deletion Syndrome | 1 | 2014 | 1 | 0.110 |
Why?
|
| Hemorrhage | 2 | 2014 | 265 | 0.110 |
Why?
|
| Ductus Arteriosus | 1 | 2014 | 4 | 0.110 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2014 | 4 | 0.110 |
Why?
|
| Injections, Intramuscular | 1 | 2014 | 22 | 0.110 |
Why?
|
| Length of Stay | 5 | 2016 | 240 | 0.110 |
Why?
|
| Reproducibility of Results | 5 | 2018 | 782 | 0.110 |
Why?
|
| Internal Mammary-Coronary Artery Anastomosis | 2 | 2012 | 4 | 0.110 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2014 | 36 | 0.110 |
Why?
|
| Friedreich Ataxia | 1 | 2015 | 47 | 0.110 |
Why?
|
| Tachycardia, Ventricular | 1 | 2014 | 60 | 0.110 |
Why?
|
| Registries | 1 | 2016 | 393 | 0.110 |
Why?
|
| Cardiology | 1 | 2014 | 48 | 0.110 |
Why?
|
| Curriculum | 1 | 2016 | 296 | 0.110 |
Why?
|
| Cor Triatriatum | 1 | 2014 | 1 | 0.110 |
Why?
|
| Tissue Expansion | 1 | 2014 | 2 | 0.110 |
Why?
|
| Vasoconstrictor Agents | 1 | 2014 | 34 | 0.110 |
Why?
|
| Prosthesis Fitting | 1 | 2014 | 5 | 0.110 |
Why?
|
| Biomarkers, Tumor | 1 | 2017 | 409 | 0.110 |
Why?
|
| DiGeorge Syndrome | 1 | 2014 | 3 | 0.110 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2014 | 96 | 0.110 |
Why?
|
| Vasopressins | 1 | 2013 | 4 | 0.110 |
Why?
|
| Vasoplegia | 1 | 2013 | 3 | 0.110 |
Why?
|
| Tricuspid Valve Stenosis | 1 | 2013 | 1 | 0.110 |
Why?
|
| Global Health | 1 | 2014 | 54 | 0.110 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2013 | 17 | 0.110 |
Why?
|
| Therapeutic Equipoise | 1 | 2013 | 1 | 0.110 |
Why?
|
| Heterografts | 1 | 2014 | 66 | 0.110 |
Why?
|
| Myocardial Bridging | 1 | 2013 | 1 | 0.110 |
Why?
|
| Blood Coagulation | 2 | 2012 | 120 | 0.110 |
Why?
|
| Embolism | 1 | 2013 | 14 | 0.100 |
Why?
|
| Interleukin-8 | 1 | 2013 | 45 | 0.100 |
Why?
|
| Chest Pain | 2 | 2013 | 26 | 0.100 |
Why?
|
| Williams Syndrome | 1 | 2013 | 2 | 0.100 |
Why?
|
| Kidney Transplantation | 1 | 2014 | 44 | 0.100 |
Why?
|
| Strongyloides stercoralis | 1 | 2013 | 2 | 0.100 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 2013 | 3 | 0.100 |
Why?
|
| Embolism, Paradoxical | 1 | 2013 | 1 | 0.100 |
Why?
|
| Academic Medical Centers | 4 | 2014 | 76 | 0.100 |
Why?
|
| Time-to-Treatment | 1 | 2013 | 29 | 0.100 |
Why?
|
| Liver Transplantation | 1 | 2014 | 56 | 0.100 |
Why?
|
| Continuity of Patient Care | 1 | 2013 | 26 | 0.100 |
Why?
|
| Interleukin-10 | 1 | 2013 | 74 | 0.100 |
Why?
|
| Disease Management | 1 | 2014 | 90 | 0.100 |
Why?
|
| Iliac Aneurysm | 1 | 2012 | 8 | 0.100 |
Why?
|
| Arteriovenous Fistula | 1 | 2012 | 16 | 0.100 |
Why?
|
| Dyspnea | 1 | 2012 | 25 | 0.100 |
Why?
|
| Enterococcus | 1 | 2012 | 19 | 0.100 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2012 | 24 | 0.100 |
Why?
|
| International Normalized Ratio | 1 | 2012 | 27 | 0.100 |
Why?
|
| Aortic Rupture | 1 | 2012 | 8 | 0.100 |
Why?
|
| Anesthesia, General | 1 | 2012 | 30 | 0.100 |
Why?
|
| Pregnancy | 2 | 2014 | 1219 | 0.100 |
Why?
|
| Drug Monitoring | 1 | 2012 | 36 | 0.090 |
Why?
|
| Surgical Procedures, Operative | 1 | 2012 | 49 | 0.090 |
Why?
|
| Self Care | 1 | 2012 | 42 | 0.090 |
Why?
|
| Interleukin-6 | 1 | 2013 | 194 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2013 | 834 | 0.090 |
Why?
|
| Multidetector Computed Tomography | 1 | 2011 | 4 | 0.090 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2012 | 91 | 0.090 |
Why?
|
| Vascular Malformations | 1 | 2011 | 5 | 0.090 |
Why?
|
| Suture Techniques | 3 | 2012 | 29 | 0.090 |
Why?
|
| Benchmarking | 1 | 2011 | 33 | 0.090 |
Why?
|
| Staphylococcal Infections | 1 | 2012 | 87 | 0.090 |
Why?
|
| Lung | 1 | 2014 | 380 | 0.090 |
Why?
|
| Syncope, Vasovagal | 1 | 2011 | 5 | 0.090 |
Why?
|
| Metabolic Syndrome | 1 | 2012 | 80 | 0.090 |
Why?
|
| Aortography | 1 | 2011 | 6 | 0.090 |
Why?
|
| Weight-Bearing | 2 | 2021 | 43 | 0.090 |
Why?
|
| Hemostasis, Surgical | 1 | 2010 | 7 | 0.090 |
Why?
|
| Mammary Arteries | 1 | 2011 | 6 | 0.090 |
Why?
|
| Factor VIII | 1 | 2010 | 19 | 0.090 |
Why?
|
| Brachiocephalic Veins | 1 | 2010 | 2 | 0.090 |
Why?
|
| Superior Vena Cava Syndrome | 1 | 2010 | 2 | 0.090 |
Why?
|
| Mitral Valve Stenosis | 1 | 2010 | 3 | 0.090 |
Why?
|
| Oxygen | 3 | 2010 | 234 | 0.080 |
Why?
|
| Preoperative Care | 3 | 2017 | 81 | 0.080 |
Why?
|
| Axillary Vein | 1 | 2010 | 1 | 0.080 |
Why?
|
| Axillary Artery | 1 | 2010 | 2 | 0.080 |
Why?
|
| Cyanosis | 1 | 2010 | 3 | 0.080 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2010 | 22 | 0.080 |
Why?
|
| Thromboembolism | 1 | 2010 | 57 | 0.080 |
Why?
|
| Atrial Appendage | 1 | 2010 | 32 | 0.080 |
Why?
|
| Circulatory Arrest, Deep Hypothermia Induced | 1 | 2010 | 3 | 0.080 |
Why?
|
| Hodgkin Disease | 1 | 2010 | 11 | 0.080 |
Why?
|
| Mesenteric Arteries | 3 | 2002 | 8 | 0.080 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2010 | 26 | 0.080 |
Why?
|
| Operating Rooms | 1 | 2010 | 20 | 0.080 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2010 | 27 | 0.080 |
Why?
|
| Fibrosis | 1 | 2010 | 134 | 0.080 |
Why?
|
| Pericardiectomy | 1 | 2009 | 3 | 0.080 |
Why?
|
| Task Performance and Analysis | 1 | 2010 | 43 | 0.080 |
Why?
|
| Down Syndrome | 1 | 2010 | 19 | 0.080 |
Why?
|
| Equipment Failure | 1 | 2009 | 31 | 0.080 |
Why?
|
| Pericarditis | 1 | 2009 | 14 | 0.080 |
Why?
|
| Ductus Arteriosus, Patent | 1 | 2009 | 13 | 0.080 |
Why?
|
| Acute Kidney Injury | 1 | 2010 | 74 | 0.080 |
Why?
|
| Catheterization, Peripheral | 1 | 2009 | 24 | 0.080 |
Why?
|
| Catheterization, Central Venous | 1 | 2009 | 38 | 0.080 |
Why?
|
| Replantation | 2 | 2013 | 7 | 0.080 |
Why?
|
| Equipment Design | 1 | 2009 | 218 | 0.070 |
Why?
|
| Sensitivity and Specificity | 3 | 2014 | 524 | 0.070 |
Why?
|
| Postpartum Hemorrhage | 1 | 2008 | 10 | 0.070 |
Why?
|
| Vascular Diseases | 1 | 2009 | 68 | 0.070 |
Why?
|
| Neoplasm Staging | 2 | 2017 | 478 | 0.070 |
Why?
|
| Factor VIIa | 1 | 2008 | 29 | 0.070 |
Why?
|
| Atrial Septum | 1 | 2007 | 2 | 0.070 |
Why?
|
| Quality of Life | 1 | 2012 | 504 | 0.070 |
Why?
|
| Communication | 1 | 2010 | 179 | 0.070 |
Why?
|
| Risk | 3 | 2015 | 137 | 0.070 |
Why?
|
| Comorbidity | 3 | 2013 | 259 | 0.070 |
Why?
|
| Polyvinyl Chloride | 1 | 2007 | 2 | 0.070 |
Why?
|
| Electrolytes | 1 | 2007 | 11 | 0.070 |
Why?
|
| Chromatography, Gas | 1 | 2007 | 18 | 0.070 |
Why?
|
| Plasma Substitutes | 1 | 2007 | 5 | 0.070 |
Why?
|
| Disease-Free Survival | 3 | 2012 | 236 | 0.070 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2007 | 28 | 0.070 |
Why?
|
| In Vitro Techniques | 1 | 2007 | 242 | 0.060 |
Why?
|
| Phenotype | 2 | 2020 | 682 | 0.060 |
Why?
|
| Disease Progression | 3 | 2014 | 475 | 0.060 |
Why?
|
| Desensitization, Immunologic | 1 | 2005 | 2 | 0.060 |
Why?
|
| Ligation | 4 | 2012 | 39 | 0.060 |
Why?
|
| Drug Hypersensitivity | 1 | 2005 | 23 | 0.060 |
Why?
|
| Surveys and Questionnaires | 3 | 2016 | 994 | 0.060 |
Why?
|
| Heparin | 1 | 2005 | 111 | 0.060 |
Why?
|
| Phenoxybenzamine | 1 | 2004 | 1 | 0.060 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2004 | 6 | 0.060 |
Why?
|
| Respiration, Artificial | 3 | 2011 | 42 | 0.060 |
Why?
|
| Shock | 1 | 2004 | 17 | 0.050 |
Why?
|
| Tertiary Care Centers | 2 | 2015 | 32 | 0.050 |
Why?
|
| Reference Values | 3 | 2013 | 199 | 0.050 |
Why?
|
| Arteries | 2 | 2002 | 66 | 0.050 |
Why?
|
| Foramen Ovale, Patent | 2 | 2014 | 4 | 0.050 |
Why?
|
| Preoperative Period | 2 | 2014 | 15 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2023 | 12 | 0.050 |
Why?
|
| Joint Diseases | 1 | 2003 | 13 | 0.050 |
Why?
|
| Confidence Intervals | 2 | 2014 | 68 | 0.050 |
Why?
|
| Marfan Syndrome | 1 | 2003 | 1 | 0.050 |
Why?
|
| Saphenous Vein | 2 | 2013 | 24 | 0.050 |
Why?
|
| Combined Modality Therapy | 2 | 2013 | 302 | 0.050 |
Why?
|
| Intensive Care Units | 2 | 2013 | 50 | 0.050 |
Why?
|
| Forced Expiratory Volume | 1 | 2002 | 17 | 0.050 |
Why?
|
| Respiratory Function Tests | 1 | 2002 | 27 | 0.050 |
Why?
|
| Autopsy | 1 | 2001 | 26 | 0.040 |
Why?
|
| Remission Induction | 2 | 2014 | 58 | 0.040 |
Why?
|
| Birefringence | 1 | 2020 | 3 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2022 | 421 | 0.040 |
Why?
|
| Systems Biology | 1 | 2020 | 22 | 0.040 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2020 | 72 | 0.040 |
Why?
|
| Endothelial Cells | 1 | 2023 | 361 | 0.040 |
Why?
|
| Blood Proteins | 1 | 2020 | 68 | 0.040 |
Why?
|
| Extracellular Matrix | 1 | 2021 | 117 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2023 | 523 | 0.040 |
Why?
|
| Optical Imaging | 1 | 2019 | 35 | 0.040 |
Why?
|
| Heart Bypass, Right | 2 | 2010 | 2 | 0.040 |
Why?
|
| Monitoring, Physiologic | 2 | 2012 | 57 | 0.040 |
Why?
|
| Recombinant Proteins | 2 | 2010 | 415 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2022 | 815 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2020 | 458 | 0.040 |
Why?
|
| Pericardial Effusion | 1 | 1998 | 12 | 0.040 |
Why?
|
| Fluoroscopy | 1 | 1998 | 36 | 0.040 |
Why?
|
| Cattle | 1 | 2019 | 388 | 0.040 |
Why?
|
| Clinical Protocols | 2 | 2010 | 46 | 0.030 |
Why?
|
| Femoral Vein | 1 | 1997 | 13 | 0.030 |
Why?
|
| Databases, Protein | 1 | 2017 | 22 | 0.030 |
Why?
|
| Catheters, Indwelling | 1 | 1997 | 19 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 1997 | 66 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2017 | 139 | 0.030 |
Why?
|
| Lymphocytes | 1 | 2017 | 90 | 0.030 |
Why?
|
| Primary Graft Dysfunction | 1 | 2016 | 2 | 0.030 |
Why?
|
| Dogs | 1 | 1997 | 510 | 0.030 |
Why?
|
| Perioperative Period | 1 | 2016 | 7 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 988 | 0.030 |
Why?
|
| Polyethylene Terephthalates | 1 | 1996 | 7 | 0.030 |
Why?
|
| Prostheses and Implants | 1 | 1996 | 28 | 0.030 |
Why?
|
| Computational Biology | 1 | 2017 | 156 | 0.030 |
Why?
|
| Contraindications | 1 | 2016 | 13 | 0.030 |
Why?
|
| Heart-Assist Devices | 1 | 2016 | 30 | 0.030 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2016 | 146 | 0.030 |
Why?
|
| Intestines | 1 | 1996 | 118 | 0.030 |
Why?
|
| Rats | 4 | 2002 | 1587 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2015 | 72 | 0.030 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2014 | 9 | 0.030 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2014 | 10 | 0.030 |
Why?
|
| Electric Countershock | 1 | 2014 | 29 | 0.030 |
Why?
|
| Cryosurgery | 1 | 2014 | 19 | 0.030 |
Why?
|
| Ventricular Pressure | 1 | 2014 | 6 | 0.030 |
Why?
|
| Regenerative Medicine | 1 | 2014 | 17 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2015 | 1494 | 0.030 |
Why?
|
| Blalock-Taussig Procedure | 1 | 2014 | 2 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2014 | 68 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2014 | 114 | 0.030 |
Why?
|
| Rare Diseases | 1 | 2014 | 9 | 0.030 |
Why?
|
| Graft Survival | 1 | 2014 | 29 | 0.030 |
Why?
|
| Morbidity | 1 | 2014 | 58 | 0.030 |
Why?
|
| Graft Rejection | 1 | 2014 | 34 | 0.030 |
Why?
|
| Blood Coagulation Tests | 1 | 2014 | 27 | 0.030 |
Why?
|
| Cost Control | 1 | 2013 | 9 | 0.030 |
Why?
|
| Nerve Block | 1 | 2013 | 7 | 0.030 |
Why?
|
| Unnecessary Procedures | 1 | 2013 | 7 | 0.030 |
Why?
|
| Mice | 1 | 2023 | 4732 | 0.030 |
Why?
|
| Atrial Pressure | 1 | 2013 | 1 | 0.030 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2013 | 5 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2014 | 107 | 0.030 |
Why?
|
| Electrophysiological Phenomena | 1 | 2013 | 16 | 0.030 |
Why?
|
| Critical Care | 1 | 2014 | 49 | 0.030 |
Why?
|
| Vulnerable Populations | 1 | 2014 | 48 | 0.030 |
Why?
|
| Critical Illness | 1 | 2014 | 66 | 0.030 |
Why?
|
| Cardiomyopathy, Restrictive | 1 | 2013 | 1 | 0.030 |
Why?
|
| El Salvador | 1 | 2013 | 1 | 0.030 |
Why?
|
| Endomyocardial Fibrosis | 1 | 2013 | 1 | 0.030 |
Why?
|
| Patient Safety | 1 | 2013 | 38 | 0.030 |
Why?
|
| Geriatric Assessment | 1 | 2014 | 91 | 0.030 |
Why?
|
| Endocardium | 1 | 2013 | 16 | 0.030 |
Why?
|
| Propensity Score | 1 | 2013 | 59 | 0.030 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2014 | 117 | 0.030 |
Why?
|
| Ultrasonography, Doppler | 1 | 2013 | 22 | 0.030 |
Why?
|
| Medical Records | 1 | 2013 | 51 | 0.030 |
Why?
|
| Blood Loss, Surgical | 1 | 2013 | 53 | 0.030 |
Why?
|
| Emigrants and Immigrants | 1 | 2013 | 22 | 0.030 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2013 | 64 | 0.030 |
Why?
|
| Lung Diseases | 1 | 2013 | 43 | 0.020 |
Why?
|
| Angina Pectoris | 1 | 2013 | 109 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 426 | 0.020 |
Why?
|
| Rats, Wistar | 3 | 1998 | 153 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2014 | 355 | 0.020 |
Why?
|
| Cerebrovascular Disorders | 1 | 2013 | 46 | 0.020 |
Why?
|
| Monitoring, Intraoperative | 1 | 2012 | 30 | 0.020 |
Why?
|
| Radial Artery | 1 | 2012 | 21 | 0.020 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2011 | 9 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2012 | 108 | 0.020 |
Why?
|
| Renal Insufficiency | 1 | 2011 | 20 | 0.020 |
Why?
|
| Heart Arrest, Induced | 1 | 2011 | 2 | 0.020 |
Why?
|
| Patient Positioning | 1 | 2011 | 23 | 0.020 |
Why?
|
| Constriction | 1 | 2011 | 14 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2011 | 21 | 0.020 |
Why?
|
| Hypothermia, Induced | 1 | 2011 | 6 | 0.020 |
Why?
|
| Dilatation, Pathologic | 1 | 2010 | 11 | 0.020 |
Why?
|
| Coronary Circulation | 1 | 2011 | 30 | 0.020 |
Why?
|
| Polytetrafluoroethylene | 1 | 2010 | 8 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 534 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2010 | 102 | 0.020 |
Why?
|
| Equipment Failure Analysis | 1 | 2010 | 37 | 0.020 |
Why?
|
| Polycythemia | 1 | 2010 | 2 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2010 | 41 | 0.020 |
Why?
|
| Renal Replacement Therapy | 1 | 2010 | 8 | 0.020 |
Why?
|
| Aerospace Medicine | 1 | 2010 | 6 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2010 | 34 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 391 | 0.020 |
Why?
|
| Temperature | 1 | 2011 | 213 | 0.020 |
Why?
|
| Contrast Media | 1 | 2010 | 96 | 0.020 |
Why?
|
| Laryngoscopy | 1 | 2009 | 6 | 0.020 |
Why?
|
| Ultrasonography, Interventional | 1 | 2010 | 39 | 0.020 |
Why?
|
| Sutures | 1 | 2009 | 15 | 0.020 |
Why?
|
| Iatrogenic Disease | 1 | 2009 | 14 | 0.020 |
Why?
|
| Respiratory Tract Infections | 1 | 2010 | 37 | 0.020 |
Why?
|
| Workload | 1 | 2010 | 43 | 0.020 |
Why?
|
| Hypertension, Pulmonary | 1 | 2010 | 34 | 0.020 |
Why?
|
| Elective Surgical Procedures | 1 | 2010 | 74 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 2009 | 21 | 0.020 |
Why?
|
| Interprofessional Relations | 1 | 2010 | 67 | 0.020 |
Why?
|
| Incidental Findings | 1 | 2009 | 13 | 0.020 |
Why?
|
| Partial Thromboplastin Time | 1 | 2008 | 18 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2011 | 215 | 0.020 |
Why?
|
| Prothrombin Time | 1 | 2008 | 21 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2009 | 95 | 0.020 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2008 | 6 | 0.020 |
Why?
|
| Infant, Premature | 1 | 2009 | 144 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 2008 | 77 | 0.020 |
Why?
|
| Obstetric Surgical Procedures | 1 | 2007 | 1 | 0.020 |
Why?
|
| Radionuclide Angiography | 1 | 2007 | 2 | 0.020 |
Why?
|
| Ventricular Dysfunction | 1 | 2007 | 7 | 0.020 |
Why?
|
| Stroke | 1 | 2011 | 256 | 0.020 |
Why?
|
| Tunica Media | 2 | 1998 | 3 | 0.020 |
Why?
|
| Tunica Intima | 2 | 1998 | 9 | 0.020 |
Why?
|
| Catheterization | 1 | 2007 | 50 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2009 | 253 | 0.020 |
Why?
|
| Endothelium, Vascular | 2 | 2002 | 328 | 0.020 |
Why?
|
| Cognition | 1 | 2010 | 327 | 0.020 |
Why?
|
| Milrinone | 1 | 2004 | 1 | 0.010 |
Why?
|
| Death, Sudden | 1 | 2004 | 15 | 0.010 |
Why?
|
| Case Management | 1 | 2004 | 11 | 0.010 |
Why?
|
| Dopamine | 1 | 2004 | 22 | 0.010 |
Why?
|
| Perfusion | 1 | 2004 | 43 | 0.010 |
Why?
|
| Epinephrine | 1 | 2004 | 37 | 0.010 |
Why?
|
| Lactates | 1 | 2004 | 20 | 0.010 |
Why?
|
| Rats, Inbred SHR | 1 | 2002 | 13 | 0.010 |
Why?
|
| Rats, Inbred WKY | 1 | 2002 | 13 | 0.010 |
Why?
|
| Nitric Oxide Synthase | 1 | 2002 | 34 | 0.010 |
Why?
|
| Cerebrovascular Circulation | 1 | 2004 | 224 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2002 | 55 | 0.010 |
Why?
|
| Cell Division | 1 | 2002 | 154 | 0.010 |
Why?
|
| Cell Count | 1 | 1998 | 86 | 0.010 |
Why?
|
| Hyperplasia | 1 | 1996 | 27 | 0.010 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 1996 | 77 | 0.010 |
Why?
|
| Microcirculation | 1 | 1996 | 113 | 0.010 |
Why?
|